134 related articles for article (PubMed ID: 23835463)
1. Bullous pemphigoid: corticosteroid treatment and adverse effects in long-term care patients.
Spivey J; Nye AM
Consult Pharm; 2013 Jul; 28(7):455-62. PubMed ID: 23835463
[TBL] [Abstract][Full Text] [Related]
2. [Cutaneous infections in bullous pemphigoid patients treated with topical corticosteroids].
Boughrara Z; Ingen-Housz-Oro S; Legrand P; Duong TA; Roujeau JC
Ann Dermatol Venereol; 2010 May; 137(5):345-51. PubMed ID: 20470914
[TBL] [Abstract][Full Text] [Related]
3. Evidence-based management of bullous pemphigoid.
Daniel BS; Borradori L; Hall RP; Murrell DF
Dermatol Clin; 2011 Oct; 29(4):613-20. PubMed ID: 21925006
[TBL] [Abstract][Full Text] [Related]
4. [One year follow-up of patients with bullous pemphigoid].
Doffoel-Hantz V; Sparsa A; Marin B; Durox H; Bonnetblanc JM; Bédane C
Ann Dermatol Venereol; 2009 May; 136(5):407-11. PubMed ID: 19442795
[TBL] [Abstract][Full Text] [Related]
5. The role of topical corticosteroids in bullous pemphigoid in the elderly.
Joly P; Fontaine J; Roujeau JC
Drugs Aging; 2005; 22(7):571-6. PubMed ID: 16038572
[TBL] [Abstract][Full Text] [Related]
6. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid.
Joly P; Roujeau JC; Benichou J; Picard C; Dreno B; Delaporte E; Vaillant L; D'Incan M; Plantin P; Bedane C; Young P; Bernard P;
N Engl J Med; 2002 Jan; 346(5):321-7. PubMed ID: 11821508
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of rituximab in a case of refractory bullous pemphigoid].
Reguiaï Z; Tchen T; Perceau G; Bernard P
Ann Dermatol Venereol; 2009 May; 136(5):431-4. PubMed ID: 19442800
[TBL] [Abstract][Full Text] [Related]
8. Topical class I corticosteroids in 10 patients with bullous pemphigoid: correlation of the outcome with the severity degree of the disease and review of the literature.
Stockman A; Beele H; Vanderhaeghen Y; Naeyaert JM
J Eur Acad Dermatol Venereol; 2004 Mar; 18(2):164-8. PubMed ID: 15009295
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study.
Du-Thanh A; Merlet S; Maillard H; Bernard P; Joly P; Estève E; Richard MA; Pauwels C; Ingen-Housz-Oro S; Guillot B; Dereure O
Br J Dermatol; 2011 Dec; 165(6):1337-43. PubMed ID: 21777222
[TBL] [Abstract][Full Text] [Related]
10. [BULLOUS PEMPHIGOID RESISTANT TO CORTICOSTEROIDS].
Sah M; Rozenman D; Cohen E; Ziv M
Harefuah; 2016 Oct; 155(10):593-595. PubMed ID: 28530051
[TBL] [Abstract][Full Text] [Related]
11. Prediction of survival for patients with bullous pemphigoid: a prospective study.
Joly P; Benichou J; Lok C; Hellot MF; Saiag P; Tancrede-Bohin E; Sassolas B; Labeille B; Doutre MS; Gorin I; Pauwels C; Chosidow O; Caux F; Estève E; Dutronc Y; Sigal M; Prost C; Maillard H; Guillaume JC; Roujeau JC
Arch Dermatol; 2005 Jun; 141(6):691-8. PubMed ID: 15967914
[TBL] [Abstract][Full Text] [Related]
12. [Prospective study of treatment of bullous pemphigoid by a class I topical corticosteroid].
Zimmermann R; Faure M; Claudy A
Ann Dermatol Venereol; 1999 Jan; 126(1):13-6. PubMed ID: 10095883
[TBL] [Abstract][Full Text] [Related]
13. [Cyclosporin in the treatment of bullous pemphigoid: preliminary study].
Barthélémy H; Thivolet J; Cambazard F; Bendelac A; Mauduit G; Granier F; Frappaz A
Ann Dermatol Venereol; 1986; 113(4):309-13. PubMed ID: 3532906
[TBL] [Abstract][Full Text] [Related]
14. Bullous pemphigoid treated with intravenous immunoglobulin.
Tuchinda P; Ritchie S; Gaspari AA
Cutis; 2014 May; 93(5):264-8. PubMed ID: 24897141
[TBL] [Abstract][Full Text] [Related]
15. Treatments of choice for bullous pemphigoid.
Cooper SM; Wojnarowska F
Skin Therapy Lett; 2002 Jan; 7(1):4-6. PubMed ID: 11859388
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of bullous pemphigoid: general corticosteroid therapy or local corticosteroid therapy?].
Verret JL
Ann Dermatol Venereol; 1999 Jan; 126(1):11-2. PubMed ID: 10095882
[No Abstract] [Full Text] [Related]
17. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV).
Borradori L; Van Beek N; Feliciani C; Tedbirt B; Antiga E; Bergman R; Böckle BC; Caproni M; Caux F; Chandran NS; Cianchini G; Daneshpazhooh M; De D; Didona D; Di Zenzo GM; Dmochowski M; Drenovska K; Ehrchen J; Goebeler M; Groves R; Günther C; Horvath B; Hertl M; Hofmann S; Ioannides D; Itzlinger-Monshi B; Jedličková J; Kowalewski C; Kridin K; Lim YL; Marinovic B; Marzano AV; Mascaro JM; Meijer JM; Murrell D; Patsatsi K; Pincelli C; Prost C; Rappersberger K; Sárdy M; Setterfield J; Shahid M; Sprecher E; Tasanen K; Uzun S; Vassileva S; Vestergaard K; Vorobyev A; Vujic I; Wang G; Wozniak K; Yayli S; Zambruno G; Zillikens D; Schmidt E; Joly P
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1689-1704. PubMed ID: 35766904
[TBL] [Abstract][Full Text] [Related]
18. Bullous pemphigoid in an infant using complementary medicine.
Purvis DJ; Bhogal BS; Harper JI
Clin Exp Dermatol; 2009 Mar; 34(2):195-8. PubMed ID: 19187301
[TBL] [Abstract][Full Text] [Related]
19. The management of oral mucous membrane pemphigoid with dapsone and topical corticosteroid.
Arash A; Shirin L
J Oral Pathol Med; 2008 Jul; 37(6):341-4. PubMed ID: 18331284
[TBL] [Abstract][Full Text] [Related]
20. [Interpretation of 2021 French Guidelines for the Therapeutic Management of Bullous Pemphigoid].
Wang SH; Zuo YG
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Oct; 44(5):828-836. PubMed ID: 36325781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
